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MALIGNANCIES OF THE THYMUS
The Role of Chemotherapy in Advanced Thymoma
Jordan Schmitt, MD,* and Patrick J. Loehrer, Sr., MD*
Background: Thymoma and thymic carcinomas are rare malignan-
cies. Most thymomas and about one-third of thymic carcinomas can
be cured with local therapy. The remainder of will be candidates for
systemic therapy. Numerous retrospective trials confirm objective
responses to a variety of single-agent and combination chemother-
apeutic regimens.
Methods: No prospective randomized comparison of regimens has
been performed because of the rarity of the disease. This paper reviewed the
literature of chemotherapy in advanced thymic malignancies.
Results: Existing data suggest that anthracycline plus cisplatin
regimens seem to demonstrate higher response rates and perhaps
longer median survival times compared with nonanthracycline-
containing regimens.
Discussion: Thymic malignancies are sensitive to a broad spectrum of
systemic agents. Thymic carcinoma has a distinct clinical presentation
and worse therapeutic outcomes than thymoma. Despite reproducible
high response rates in thymoma, durable complete remissions are rare.
Thus, novel new therapeutic targets need to be identified and appropri-
ate agents developed to have further impact on this disease.
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Approximately one third of patients with thymoma willhave invasive or advanced unresectable disease at the time
of diagnosis.1–3 These patients often have either local invasion
into neighboring organs, pleural, or pericardial dissemination or
less commonly extrathoracic metastasis to the liver, bone, brain,
or kidney.4 According to Masaoka et al.,5 those with invasive
disease and those with metastatic disease have 5-year overall
survivals estimated at 67% and 50%, respectively. Because of
the rarity of thymomas, the published experience with chemo-
therapy has been limited, but there have been numerous case
reports and small prospective trials documenting that thymomas
are a chemotherapy-sensitive disease and that systemic chemo-
therapy is capable of producing durable remissions in those
patients with advanced or metastatic thymoma.
Historically, various chemotherapy agents have dem-
onstrated activity as single agents in thymoma (Figure 1).
There have been only a few small phase II trials looking at
single-agent chemotherapy for advanced thymoma. These
include cisplatin, interleukin-2, pemetrexed, and ifosf-
amide. All trials included patients who had been previ-
ously treated with chemotherapy. This article will review
the salient articles evaluating the role of chemotherapy or
thymic tumors. The role of targeted agents will be dis-
cussed elsewhere in this issue.
SINGLE-AGENT THERAPY
As mentioned, much of the published experiences of
single agents in thymic malignancies have focused on case
reports in small retrospective series. In most of these, the
predominant histology studied has been thymoma. In the
1970s and early 1980s, a number of case reports suggested
activity with cisplatin or doxorubicin-based therapy. One of
the first articles described a complete remission in a patient
with renal metastases from thymoma who was treated with
cisplatin.6 This was followed shortly thereafter by the earliest
published prospective phase II trial in thymoma, which was
conducted by the Eastern Cooperative Oncology Group
(ECOG) and evaluated cisplatin (50 mg/m2 every 3 weeks) in
patients with advanced/metastatic thymoma.7 In this study,
21 patients were eligible for assessment, and two (10%)
demonstrated a partial remission. No complete remissions
were noted. Median survival was reported as 76 weeks for all
patients on the study with a 2-year survival estimated at 39%.
From 1984 to 1996, several British investigators looked
at ifosfamide as single-agent therapy in invasive thymoma.8
Two different regimens of ifosfamide plus mesna were used.
The most common toxicities were nausea, vomiting, and
leucopenia. Five complete responses and one partial response
were noted in the 13 (overall response, 46.2%) assessable
patients. Two of the patients had thymic carcinoma and had
stable disease as the best response to therapy. The median
duration of complete response was 66 months, and the esti-
mated survival rate 5 years after ifosfamide therapy was 57%.
Based on both a case report showing complete response
and the lymphocytic effect of interleukin (IL)-2 (activation of
cytolytic T-lymphocytes),9 IL-2 for the treatment of thymoma
was further investigated in a 14-patient phase II clinical trial
performed at Indiana University.10 This trial enrolled previ-
ously treated patients with thymoma between 1992 and 1994.
Eligible patients were treated with IL-2 at 12  106 IU/m2/d
subcutaneously daily for 5 days for 4 weeks followed by 2
weeks of rest. The median number of cycles received was
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two. Five of the 14 patients required dose reductions for
grade 3 toxicities. Two patients developed new signs of
myasthenia gravis while on study. Results of the trial re-
vealed no objective responses.
Twenty-seven previously treated patients (16 thymoma
and 11 thymic carcinoma) were treated with single-agent
pemetrexed. Toxicity was mild with no patient experiencing
grade IV toxicity. Two complete and two partial responses
(RECIST criteria) were observed among the patients with
thymoma, and one partial response in a patient with thymic
carcinoma was noted. The median overall survival was 29
months for all patients.
A case report by Palmieri et al.11 reported a complete
response and resolution of pure red cell aplasia in a patient
treated with high-dosage octreotide (1.5 mg/d/subcutaneously)
plus prednisone (0.6 mg/kg/d). The report was followed by a
trial conducted through ECOG, which evaluated octreotide
alone for two cycles and if no objective response was seen,
prednisone was added to regimen.12 In this trial, 32 patients with
thymoma and six patients with thymic carcinoma or carcinoid
were evaluable. Eight patients had grade 4 or 5 toxicity including
one death secondary to grade 5 infectionwithout neutropenia. Of 38
patients treated with octreotide alone, four (10.5%) had an objective
response. For the 21 patients in whom prednisone was added to
octreotide, there were two complete and six partial responses noted.
The objective response rate for all patients was 30.3%.
Other case reports have demonstrated response to rarely
of agents including 5-fluorouracil, gemcitabine, paclitaxel,
navelbine, maytansine, suranim, and gallium nitrate.13–15
Several phase II trials with targeted agents such as gefitinib,
imatinib, and erlotinib plus bevacizumab have been con-
ducted and have shown no significant activity in patients with
thymic carcinoma or thymoma. These will be discussed
elsewhere in this monography.
COMBINATION CHEMOTHERAPY
In the 1980s and early 1990s, combination chemotherapy
in advanced thymic malignancies became more popular. Hu et
al. published a review of trials and case reports in 1986, which
concluded that thymoma seems to be sensitive to corticosteroids
(11/13 patients with documented response) and to platinum-
based combination chemotherapy (84% response rate [10/25
with complete response and 11/25 with partial response]). They
also speculated that the response seen in nonplatinum-based
chemotherapy was likely related to the concurrent use of corti-
costeroids and not to the chemotherapeutic agents themselves.16
Multiple phase II trials and case series have been published to
evaluate various combinations. The majority of clinical trials
focused on platinum-based combination chemotherapy (Table
1). Most of these regimens containing both cisplatin and doxo-
rubicin have reported objective response rates ranging from 50
to 92%.17
FIGURE 1. Active chemotherapy agents in thymoma.13,18
TABLE 1. Platinum-Based Combination Chemotherapeutic Regimens for Patients with Thymoma
Regimen Agents
No. of
Patients CR PR % CR  PR
Average Survival
Duration (yr) References
PAC Cisplatin, doxorubicin, and cyclophosphamide 30 3 12 50 3.2 Loehrer et al.18
PAC  XRT Cisplatin, doxorubicin, and cyclophosphamide 23a 5 11 70 5 Loehrer et al.19
PACP PAC  prednisone 12a 3 8 92 NR Shin et al.27
ADOC Doxorubicin, cisplatin, vincristine, and
cyclophosphamide
32 15 14 90 1.25 Fornasiero et al.21
ADOC Doxorubicin, cisplatin, and vincristine,
cyclophosphamide
16 1 12 81 4 Berruti et al.28
ADOC Doxorubicin, cisplatin, and vincristine,
cyclophosphamide
16a 7 5 75 NR Rea et al.29
PEpE Cisplatin, epirubicin, and etoposide 7a 4 2 86 NR Macchiarini et al.30
VIP Etoposide, ifosfamide, and cisplatin 28 0 9 32 2.5 Loehrer et al.17
PE Cisplatin and etoposide 16 5 4 56 4.3 Giaccone et al.22
BAPP Bleomycin, adriamycin, cisplatin, and prednisone 9 1 5 67 NR Chahinian, 1983
Carboplatin and taxol 44 3 11 35 Lemma et al.23
aLimited stage disease only.
CR, complete response; PR, partial response; NR, not reported; XRT, radiation therapy.
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One of the first prospective phase II trials with combi-
nation chemotherapy was completed by the ECOG. In 30
patients with stage IV thymoma or thymic carcinoma, 15 had
an objective response to cisplatin (50 mg/m2), doxorubicin
(50 mg/m2), and cyclophosphamide (500 mg/m2) (PAC)
administered every 3 weeks. The median duration of response
was 12 months, and the 5-year overall survival was 32%.18
In patients with limited, unresected thymoma, treat-
ment consisting of PAC for 2 to 4 cycles followed by
radiotherapy to the involved field (54 Gy). Among 23 fully
evaluable patients, five complete and 11 partial responses
were observed. The median time to treatment failure was 93
months, and the median overall survival was 93 months
(range, 1–110 months). The 5-year survival was 52%.19
Similar results of high-degree activity were reported by
Kim et al.,20 in which they used a regimen of cisplatin,
doxorubicin, cyclophosphamide plus prednisone (CAPP). In
this series largely composed of patients with locally advanced
thymoma, 17 of 22 (77%) patients had an objective response
to therapy. Three patients had a complete response to therapy.
Responding patients underwent surgical resection followed
by radiation therapy. The median survival time of the group
of patients was not reached at the time of the publication.
Fornasiero et al.21 used the doxorubicin, cisplatin, vin-
cristine, cyclophosphamide regimen (cisplatin, vincristine,
doxorubicin, and cyclophosphamide). In these retrospective
analyses, 34 of 37 patients achieved a partial (48%) or
complete (43%) response. The median survival, however,
was only 15 months, which questions the value of the addi-
tion of vincristine to the PAC regimen.
Several regimens have evaluated combinations which
exclude anthracycline. The first prospective trial of this na-
ture was led by Giaccone et al.,22 for the European Organi-
zation for Research and Treatment of Cancer. In the trial, 16
previously untreated patients with advanced thymoma were
treated with cisplatin plus etoposide. Five complete and four
partial responses were noted for an overall response rate of
56%. The median survival time was 51.6 months.
Attempting to build on this experience, the ECOG
conducted a prospective trial in thymic malignancies (thy-
moma and thymic carcinoma) using cisplatin plus etoposide
with the addition of ifosfamide (VIP).17 In 28 evaluable
patients, only nine (32%) had an objective response. The
median survival time was 31.6 months. This trial that used a
drug with single-agent activity, ifosfamide, seemed to ques-
tion the backbone of a cisplatin, etoposide regimen as stan-
dard frontline therapy.
Further evidence against nonanthracycline-containing
regimens as part of first-line therapy came from another
ECOG trial. In this trial by Lemma et al.,23 45 patients with
thymoma (N  24) or thymic carcinoma (N  21) were
treated with carboplatin (area under the curve  6) plus
paclitaxel (225 mg/m2) every 3 weeks. Overall, a 28.6%
objective response rate was observed for patients with thymic
carcinoma and a 34.8% for those with thymoma. The pro-
gression-free survival was 5.0 and 16.8 months, respectively.
The role of high-dose chemotherapy followed by au-
tologous stem-cell transplant has not yet been established.
Iwasaki et al. published a report of two cases of advanced
thymoma who received standard chemotherapy (ADOC) fol-
lowed by high-dose ifosfamide, carboplatin, and etoposide
with autologous stem-cell rescue. They observed one patho-
logic CR and one pathologic PR.24 Another study looking at
the role of autologous transplantation in poor-risk malignan-
cies included two patients with relapsed thymoma. In this
series, both patients achieved a CR after high-dose chemo-
therapy with BEAM (semustine, etoposide, cytarabine, and
melphalan) and autologous stem-cell transplant.25 Finally, a
series from Indiana University was reported on four patients
with platinum-sensitive, relapsed thymoma who underwent
salvage therapy with high-dose carboplatin and etoposide
followed by autologous stem-cell transplant. They noted that
three patients maintained the PR achieved after initial che-
motherapy, and the fourth patient maintained the previously
achieved CR with acceptable toxicity.26 No durable responses
were noted.
With the role of transplantation not yet clearly defined,
salvage therapy with targeted agents has been the focus of
ongoing research. Other combination therapies include tar-
geted agents, which are discussed in another chapter. A trial
with erlotinib plus bevacizumab failed to demonstrate mean-
ingful activity. As mentioned in the chapter by Rajun and
Giaccone in this journal, the histone deacetylase inhibitor,
belinostat, demonstrated single-agent activity in recurrent
thymic tumors. As such, belinostat plus PAC is currently
being evaluated in previously untreated patients with ad-
vanced thymoma through an ongoing trial at the National
Cancer Institute and the Indiana University Melvin and Bren
Simon Cancer Center.
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